Table 4.
Risk of CIN3 by second HPV genotype 12 months after a baseline screening result for HPV-positive and NILM cytology. Concordant results by HPV genotype are in italic.
| 12-month-year follow-up HPV test results | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HPV16 | HPV18 | Other high-risk HPV | Any high-risk HPV (HPV16, 18, and other high risk) | |||||||||||||
| Baseline HPV test results | N (cases) | N | Risk | 95%CI | N (cases) | N | Risk | 95%CI | N (cases) | N | Risk | 95%CI | N (cases) | N | Risk | 95%CI |
| HPV16 | 31 | 105 | 29.5 | 21.8–39.3 | 0 | 0 | –c | – c | 0 | 4 | –c | –c | 31 | 109 | 28.4 | 21.9–37.9 |
| HPV18 | 0 | 0 | –c | – c | 5 | 32 | 15.6 | 6.8–33.5 | 1 | 4 | 25.0 | 4.0–87.2 | 6 | 36 | 16.7 | 7.9–33.4 |
| Other high-risk HPV | 0 | 12 | – c | – c | 1 | 5 | 20.0 | 3.1–79.6 | 41 | 402 | 10.2 | 7.6–13.6 | 42 | 419 | 10.0 | 7.5–13.3 |
| Any high-risk HPV | 31 | 117 | 26.5 | 19.4–35.5 | 6 | 37 | 16.2 | 7.6–32.6 | 42 | 410 | 10.2 | 7.7–13.6 | 79a | 564b | 14.0 | 11.4–17.2 |
CIN cervical intraepithelial neoplasia, CI confidence interval, NILM negative for intraepithelial lesion or malignancy.
aExcludes 62 individuals with missing genotype data out of 626 (9.9%) individuals who were HPV positive a second time after baseline HPV-positive and NILM results.
bExcludes 9 individuals with missing genotype data out of 88 (0.1%) individuals who were HPV positive a second time after baseline HPV-positive and NILM results.
cSample size insufficient to yield meaningful results.